Valuation: Microbio Co., Ltd.

Market Cap 9B 282M 251M 234M 214M 403M 27.16B 406M 2.84B 1.1B 13.88B 1.06B 1.04B 44.56B P/E 2024
-17.6x
P/E 2025 -14.3x
Enterprise Value 7.04B 221M 196M 183M 167M 315M 21.23B 318M 2.22B 859M 10.86B 829M 811M 34.84B EV / Sales 2024
10.1x
EV / Sales 2025 4.71x
Free-Float
66.85%
Yield 2024 *
-
Yield 2025 -
08-12 Microbio Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-11 Microbio Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-27 Microbio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-11 Microbio Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-07 Microbio Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-11 Microbio Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-17 Microbio Announces Promising Results Of MS-20 As Add-On Therapy For Ulcerative Colitis RE
25-03-17 Microbio Co., Ltd. Announces Promising Results of MS-20 as an Add-on Therapy for Ulcerative Colitis CI
25-03-10 Microbio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-12-16 Microbio Co., Ltd. Announces Promising Results of MS-20 in Combination with Keytruda for Stage IIIb/IV Non-Small Cell Lung Cancer CI
24-11-13 Microbio Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-09-08 Microbio Co., Ltd. Announces SNS812 Phase 2 Study Demonstrated Statistical Significance in Treating Covid-19 Based on Its Safety, Precision and Broad-Spectrum Efficacy by Its Subsidiary Microbio Co.,Ltd CI
24-08-11 Microbio Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
1 day+0.99%
1 week+3.03%
Current month-0.33%
1 month+5.15%
3 months-10.79%
6 months-11.30%
Current year-17.30%
1 week 14.65
Extreme 14.65
15.45
1 month 14.1
Extreme 14.1
15.45
Current year 13.6
Extreme 13.6
21.85
1 year 13.6
Extreme 13.6
22.8
3 years 13.6
Extreme 13.6
58.76
5 years 13.6
Extreme 13.6
70.65
10 years 8.41
Extreme 8.410711
115.15
Manager TitleAgeSince
Chief Executive Officer - 2021-12-19
Director of Finance/CFO - 2015-02-28
Chief Tech/Sci/R&D Officer - 2008-06-30
Director TitleAgeSince
Director/Board Member 73 2011-02-13
Director/Board Member 86 2011-02-13
Director/Board Member 64 2006-05-28
Change 5-day change 1-year change 3-year change Capi.($)
+0.99%+3.03%-32.30%-66.57% 282M
+0.20%-3.10%+0.78%-27.14% 232B
+0.74%-3.42%-7.15%-13.92% 74.27B
0.00%-0.82%+82.95%+549.41% 44.22B
+2.67%-0.74%-19.19%+13.93% 42.8B
+1.17%-0.83%+31.80%+9.00% 38.77B
+0.56%-3.71%-17.91%-18.76% 32.19B
-0.91%+3.19%+24.99%+83.59% 31.54B
+0.79%-2.24%-14.86%-12.69% 28.38B
-1.20%-6.09%-14.85%-32.98% 26.31B
Average +0.50%-1.76%+3.43%+48.39% 55.07B
Weighted average by Cap. +0.44%-2.55%+5.67%+33.95%

Financials

2024 2025
Net sales 1.72B 54.08M 48.05M 44.85M 40.88M 77.1M 5.2B 77.82M 543M 210M 2.66B 203M 199M 8.53B 1.89B 59.46M 52.83M 49.31M 44.94M 84.76M 5.72B 85.55M 597M 231M 2.92B 223M 218M 9.38B
Net income -1.1B -34.56M -30.7M -28.66M -26.12M -49.26M -3.32B -49.72M -347M -134M -1.7B -130M -127M -5.45B -758M -23.79M -21.14M -19.73M -17.98M -33.91M -2.29B -34.23M -239M -92.5M -1.17B -89.31M -87.37M -3.75B
Net Debt -1.94B -60.8M -54.02M -50.42M -45.95M -86.67M -5.84B -87.48M -610M -236M -2.99B -228M -223M -9.59B -1.96B -61.62M -54.75M -51.1M -46.57M -87.84M -5.92B -88.66M -618M -240M -3.03B -231M -226M -9.72B
Logo Microbio Co., Ltd.
Microbio Co., Ltd. is a Taiwan-based company primarily engaged in the research, development, manufacture, distribution and wholesales of healthcare food products and pharmaceuticals. The Company provides fermentation products, including Tien Chun Bao (TCB) oral solutions; herbal products, including LeeHerb series products, as well as organic foods, including vegetables, fruits, nuts, pastry, seasonings, organic meals and others. In addition, it provides new medicines, including anticancer medicines, medicines for hepatitis, allergy, rheumatoid arthritis and others. The Company mainly distributes its products mainly within domestic market.
Employees
-
Date Price Change Volume
26-10-02 NT$15.30 +0.99% 791,367
26-10-01 NT$15.15 -1.30% 1,199,642
26-09-30 NT$15.35 +2.33% 1,725,507
26-09-29 NT$15.00 +1.01% 1,201,076
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. 4128 Stock